Purpose. This study was designed to elucidate the role of amplification at 8q24 in the pathophysiology of ovarian and breast cancer since increased copy number at this locus is one of the most frequent genomic abnormalities in these cancers. Experimental Design. To accomplish this, we assessed the association of amplificaiton at 8q24 with outcome in ovarian cancers using FISH to tissue microarrays and measured responses of ovarian and breast cancer cell lines to specific small interfering RNAs (siRNA) against the oncogene, MYC, and a putative noncoding RNA, PVT1, both of which map to 8q24. Results.
INTRODUCTION
Amplification of a region on chromosome 8q24 is one of the most frequent events in carcinomas including serous ovarian and breast cancers and has been associated with reduced survival duration in some studies (1, 2) . The well-established oncogene, MYC, maps to this locus and likely contributes to the pathophysiology of cancers in which it is amplified. However, the PVT1 transcript also maps to this region and has been implicated in cancer pathophysiology as well (3) . In mouse, for example, the pvt-1 locus is a site of recurrent translocation in plasmacytomas (4, 5) and is a common site of tumorigenic retroviral insertion in lymphomas (6) . In humans, the region homologous to pvt-1 is a site of recurrent translocation between chromosomes 2 and 8 (7, 8) and its first exon is co-amplified with MYC in colon carcinoma cell lines (9) . PVT1 has been suggested as a MYC activator (10), however, little evidence exists to support that role. Moreover, evidence is now emerging that PVT1 may act as a noncoding RNA (Huppi et al., private communication) that is strongly conserved between mouse and human.
We now present evidence that both PVT1 and MYC contribute to ovarian and breast cancer pathophysiology when over expressed by amplification at 8q24. First, we show that amplification at this locus is associated with reduced survival duration in ovarian cancer. We also show that down-regulation of either PVT1 or MYC expression using small interfering RNA (siRNA) technology inhibits proliferation in ovarian and breast cancer cell lines in which they are amplified and over expressed but not in cell lines in which they are not over expressed. In addition, we show that inhibition of PVT1 but not MYC induces an amplification/over expression-specific apoptotic response. Our analyses of PVT1 transcripts are consistent with the interpretation that PVT1 exerts its pathophysiological influence as a noncoding RNA (Private communication with Dr. Konrad Huppi). S1). The known biological properties of the cell lines are summarized in Table S1 . Breast cancer cell lines with and without amplification at 8q24 were selected from a collection of 51 well-characterized lines described by Neve et al. (11).
Nucleic acid extraction. Genome DNA and total RNA were purified from cultured cells as described previously (11). Total RNA from a panel of normal human tissues was purchased from Clontech (catalogue number: 636643) and used to measure relative expression levels of PVT1.
Genome copy number and expression analysis. Relative genome number was assessed in the 30 ovarian cell lines using array CGH with three BAC arrays as described previously (12, 13). These included: (a) Hum2.0 arrays comprised of 2465 BACs selected at approximately megabase intervals along the genome (12, 14) . (b) Arrays comprised of 1860 BACs selected to include genes known to be involved in cancer pathogenesis (15) . (c) Arrays carrying 400 BACs selected to tile across 13 Mbp at 3q26, 15 Mbp at 8q24, and 30 Mbp at 20q centered on regions of recurrent amplification associated with reduced survival 5 duration in earlier studies (15) . Global gene expression was assessed by hybridization to Affymetrix U133A arrays in the J David Gladstone Institutes in University of California, San Francisco as described (www.affymetrix.com). Hybridized arrays were visualized with Affymetrix Microarray Suite 5.0® (MS5.0). The image files of all the arrays were then analyzed together with the robust multiarray average (RMA) algorithms (16) . Genome copy number and expression analyses of the breast cancer cell lines used in this study are described by Neve et al.(11).
Real-time Quantitative-PCR (QPCR) Analysis. QPCR was performed essentially as described previously (17) . Quantitative detection of specific nucleotide sequences was based on the fluorogenic 5' nuclease assay and relative expression was calculated as described (17) . Assays were purchased as Assays-onDemand from Applied Biosystems. The catalogue numbers of these assays are listed in Table S2 . The sequences of PCR primers and Taqman probe specific for PVT1 transcription unit were designed with ABI Primer Express 2.0 software based on the sequence of a published expressed sequence tag (EST) clone for human PVT1 (NCBI accession number: M34428). The primer sequences for PVT1 were: sense-CATCCGGCGCTCAGCT, antisense-TCATGATGGCTGTATGTGCCA. The Taqman probe was 5'-FAM-CTGACCATACTCCCTGGAGCCTTCTCC-BHQ1-3'. Primer and probe concentrations of 500 nM and 200 nM, were used respectively. "No reverse transcriptase" analyses were performed on all samples to confirm that genomic DNA was not present. For normalization, cDNA equivalent to the amount of RNA used in target gene measurements was measured for ribosomal 18S, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cyclophilin A.
Transfection of siRNA. siRNAs against PVT1 and MYC were either designed using the 'Biotool' function available at www.idtdna.com and purchased from Integrated DNA Technologies (IDT, 6 Coralville, IA) or ordered from Dharmacon (Lafayette, CO) pre-designed siGENOME™ Collection. Two siRNAs cognate to different parts of mRNA sequence of PVT1 (siPVT1a and siPVT1b) and two siRNAs cognate to different parts of MYC (siMYCa and siMYCb) were used in this study. Plasmids containing the desired 5'RACE PCR product were isolated and purified from single bacterial colonies. They were then sequenced with M13 forward and reverse sequence primers. The sequences of individual PVT1 exons were queried on http://microrna.sanger.ac.uk/sequences/search.shtml for potential stem-loop' structures commonly observed in micro RNAs (miRNA) (19, 20) .
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RESULTS
Genome copy number and transcriptional analyses. We applied fluorescence in situ hybridization (FISH; Figure 1a ) for analysis of 380 ovarian tumors arranged in tissue microarrays with probes to the MYC locus (8q24) and the chromosome 8 centromere. This analysis showed that a MYC locus copy number to centromere copy number ratio > 1.5 (amplification) was significantly higher in serous tumors (p<0.0001) and was associated with reduced survival duration (p=0.0170; Figure 1b ).
We assessed the mechanisms by which amplification at 8q24 contribute to ovarian and breast pathophysiology by analyzing the effects of reducing expression levels of transcripts encoded in the region of recurrent amplification in cell lines with and without amplification at this locus. We identified ovarian cell lines amplified at this locus by applying array CGH (aCGH) to 30 ovarian cancer cell lines.
Most regions of recurrent genome copy number abnormality including amplification at 8q24 in the cell lines were similar to those in primary serous ovarian tumors ( Figure 1c and 1d) (21) . The raw aCGH data has been deposited to http://www.ebi.ac.uk/cgi-bin/microarray/tab2mage.cgi, accession # E-TABM-246. Table S3 Table   S4 . We used QPCR to analyze the expression levels of 57 transcripts (listed in Table S2 ) encoded in regions of recurrent copy number abnormality previously implicated in the pathophysiology of ovarian cancer. We analyzed these transcript levels in 21 cell lines (bold highlighted in Table S1 ) to determine the accuracy with which the microarray analyses estimated expression levels. Figure S1 shows correlation coefficients between QPCR and microarray results calculated for each gene in the 21 ovarian cancer cell lines. The correlation coefficients between expression levels measured using QPCR and Affymetrix array analysis were mostly high (average correlation coefficient 0.75) except for 5 genes including PVT1 for which the correlation coefficients were very low to negative.
Since we observed some discordances between transcript levels measured using QPCR and Affymetrix expression array analysis, we measured transcript levels of the transcripts for PVT1 and MYC using QPCR in 20 ovarian cancer cell lines. The Affymetrixc U133A arrays used in this study carried probe sets 216240_at and 216249_at that were designed from EST clone M34428. The array signals for both probe sets were either undetectable or very low across all the lines whereas the Taqman analyses designed from the same source EST sequence detected significant and variable expression levels in the same cell lines (Table1). The Pearson's correlation between PVT1 expression levels measured by microarray and by 11 QPCR was only -0.02 and -0.01 for 216240_at and 216249_at, respectively, while the correlation between PVT1 transcript levels measured using QPCR and genome copy number at 8q24 was high (Table 1) . We attribute these discordances to the poor performance of the probe sets for PVT1 on the microarrays. Table   1 compares aCGH measurements of genome copy number at 8q24 and QPCR analyses of expression levels for PVT1 and MYC in 20 of the ovarian cancer cell lines. Genome copy number was assessed at the BAC array probe closest to PVT1 and MYC (clone VYS08A2679). The starting site of this BAC clone overlaps with 5' end of the MYC locus and 3' end of the clone is ~50kbp downstream of 5' end of the PVT1 transcription unit. Both PVT1 and MYC transcript levels were strongly correlated with genome copy number in the 20 ovarian cancer cell lines tested. Interestingly, the correlation between copy number and expression level was higher for PVT1 than for MYC; 0.89 and 0.64, respectively. This is due to the fact that some cell lines (e.g. OVCA432 and OVCAR8) with amplification at 8q24 did not over express MYC while transcription levels of PVT1 were high in all lines (e.g. CAOV4, HEY, OVCA432 and OVCAR8) showing amplification at 8q24. In most cell lines, transcription levels of MYC and PVT1 were significantly higher where they were amplified than in cell lines in which they were not. However, PVT1
was highly expressed in cell line TOV21G, even though it was not amplified suggesting another mechanism of over expression. We also compared transcription levels of PVT1 in 18 different normal tissues, 3 breast cancer lines (SKBR3, HBL100 and SUM159T), and 2 normal ovarian cell lines (OSE1157 and IOSE29) to those in two 8q24 amplified ovarian cancer lines (CAOV4 and HEY) using QPCR. PVT1 was expressed in several of the tissues tested with highest expression in trachea but not at levels found in the two ovarian cancer cell lines. Breast cell lines generally expressed PVT1 at much lower levels than ovarian cells. Two different sequences (#1 and #2 in Figure S2 ) were obtained from OSE1157 5'RACE. Only one sequence was detected in plasmids isolated from 6 bacterial colonies that were transformed with 5'RACE PCR products from HEY cells. The HEY sequence was identical to the 5'RACE sequence #2 from OSE1157. We then searched human expressed sequence tag (EST) databases using NCBI Nucleotidenucleotide BLAST (blastn) based on our 5'RACE sequences and the sequence of a cDNA clone (NCBI accession #: BC033263) that was previously considered to be a full-length clone for PVT1. The 125bp at the 3' ends of both 5'RACE sequences overlapped with the 5' end of the BC033263 sequence. ESTs that had over 95% sequence homology with the query sequences were assembled to predict full length transcripts. The web tool, NIX (Nucleotide Identify X software, http://www.hgmp.mrc.ac.uk/NIX), was used to identify exons from these EST alignments. Nine exons were predicted for each of the two PVT1 full-length transcripts ( Figure 2 ) assembled from sequences of 5'RACE #1 and #2 and BC033263. The two transcripts shared exons 2-9 but had different first exons. We termed the first exon that corresponds to 5'RACE sequence #1 as exon 1a and the exon that corresponds to 5'RACE sequence #2 as exon 1b. Exon 1a is upstream of exon 1b in the genome (Figure 2) . In order to determine whether or not the predicted full-length transcripts exist in the transcriptome, primers against exon 1a or 1b and exon 9 were used to Printed: 05/04/07 PVT1 amplification in cancer 13 amplify PVT1 cDNAs from the HEY cells and normal testis. PCR products were then cloned and sequenced. As shown in Figure 2 , multiple alternatively spliced variants were identified from these PCR products. Predicted exons 4 and 8 were missing in all of the 22 PCR products that we have cloned. We also assessed the sequences of individual PVT1 exons detected by PCR for possible stem-loop structures that could signify the presence of transcripts that will be bound and cleaved by Drosha to liberate ~70nt miRNA precursors (22). Sequences homologous to known stem-loop structures in different species were found in predicted exons 5, 6, 7, and 9; however, the significance indices of these predictions were low in all cases.
Biological responses to inhibition of PVT1 and MYC expression. Since our main goal in this study was to determine how PVT1 and MYC contribute to ovarian cancer pathophysiology when over expressed by amplification or other genomic mechanisms, we compared biological responses to inhibition of PVT1 and MYC in ovarian and breast cancer cell lines with and without amplification and over expression of these two genes.
We assessed the biological effects of inhibiting mRNA levels of PVT1 using siRNAs in the ovarian cancer cell lines CAOV4, HEY, OVCA432 and OVCAR8 where 8q24 is amplified and PVT1 is over and HEY cells in which both PVT1 and MYC are amplified and over expressed ( Table 2) . Neither G 1 cell cycle arrest nor reduction in S-phase was seen in any of the four PVT1/MYC non-amplified/over expressed cell lines. siPVT1b had even stronger anti-proliferation effects in CAOV4 and HEY cells than siPVT1a ( Table 2 ). We also evaluated the effect of siRNA knock-down with siPVT1a on cell growth 15 using CTG assays. Table 2 shows that the number of viable cells in siPVT1a transfected HEY cells started to decrease relative to that of cells treated with Lipofectamine alone or siControl at 8 h. By 24 h, the viable cell count was only 40% of that of control cultures. In contrast, siPVT1a had no effect on cell viability in two ovarian cell lines in which PVT1 was not amplified or over expressed.
In order to determine the generality of the phenotype resulting from PVT1 knock-down, we also compared the effect of siPVT1a transfection in two breast cancer cell lines (SUM159PT and HBL100) in which PVT1 is both amplified and over expressed with that in a breast line (SKBR3) where PVT1 is only amplified but not over expressed. As shown in Table 2 , transfection of siPVT1a decreased the proportion of BrdUrd incorporating cells in SUM159PT and HBL100 but not in SKBR3. 
Knock-down of PVT1 but not MYC increases apoptosis. We assessed the effects of inhibiting
DISCUSSION
Several published findings implicate PVT1 in aspects of cancer pathophysiology. Examples include observations that rearrangement of the region at 8q24 encoding MYC and PVT1 is frequently involved in human leukemias and lymphomas (4, 5) , the regions is frequently amplified in solid tumors (2) and a site of recurrent tumorigenic viral integration in mice (26) . MYC is well established as an oncogene in this region. We now provide functional evidence for the importance of increased expression of PVT1 in cancer through analysis of cell lines with and without amplification at 8q24. These cell lines were selected from a collection of 30 ovarian cell lines described in this paper and 51 breast cancer cell lines described elsewhere (11). Our analyses of both collections show that the recurrent genome aberrations and the resulting deregulation of gene expression are highly concordant between primary tumors and the cell lines. Thus, the aspects of amplification dependent cancer pathophysiology discovered in the cell lines are likely to be obtained in primary tumors as well. 17 The strongest evidence for the importance of PVT1 in cancer pathophysiology is our observation that siRNA silencing of PVT1 expression decreases cell proliferation and increases apoptosis in breast and ovarian cancer cell lines in which it was amplified and over expressed but not in cell lines where it is not amplified/over expressed. The amplification/over expression-specific response phenotypes argue that the observed effects are due to down regulation of PVT1 rather than to off-target effects of siRNA. The PVT1 specificity of the response is further supported by our observation that the same amplification/over expression-specific response phenotype was seen using two different siRNAs against PVT1.
PVT1 has been suggested to function as a MYC activator. However, our demonstration that PVT1 inhibition does not alter MYC levels in most of the cell lines where it influences both apoptosis and proliferation argues against this. Moreover, inhibition of PVT1 but not MYC induces apoptosis in cell lines where they are both amplified and over expressed. If PVT1 were acting through MYC, the apoptotic response should have been observed after inhibition of MYC. Therefore, we conclude that PVT1 acts independently of MYC in generation of the apoptotic phenotype.
The strong induction of apoptosis resulting from siRNA inhibition of PVT1 suggests that PVT1 amplification contributes to the oncogenic phenotype, at least in part by suppressing apoptosis. This suggests the interesting possibility that amplification at 8q24 might have two simultaneous oncogenic functions: over expression of MYC, which stimulates proliferation, and over expression of PVT1, which not only stimulates proliferation but also inhibits the apoptotic response normally associated with over expression of MYC. The apoptosis suppression function of PVT1 may also explain why its over expression is associated with reduced survival duration in patients treated with platinum plus taxanebased therapies. Platinum compounds produce apoptotic responses through production of DNA cross-18 links (27) while taxanes, trigger apoptotic responses by stabilizing otherwise dynamic microtubules that are important for centrosome and mitotic spindle function (28) . Over expression of PVT1 may contribute to resistance to these agents by suppressing the apoptotic mechanisms through which they work. This possibility is partially supported by our finding that two ovarian cancer cell lines with high level PVT1 expression do not exhibit significant apoptotic responses to treatment with paclitaxel at concentrations that induced apoptosis in the other cell lines. However, PVT1 is not the only determinant of response since two other PVT1 amplified/over expressed cell lines exhibit a significant apoptotic response to paclitaxel.
Elucidation of the mechanism(s) by which PVT1 over expression contributes to suppression of apoptosis and proliferation is complicated by the fact that PVT1 is transcribed into multiple splice forms that vary in form and abundance between cell lines (data not shown and (9)). However, our observation that siRNAs complementary to sequences in exons 2 and 3 both produced phenotypes that were specific to cell lines with amplification and over expression of PVT1 suggested that transcripts containing these two exons are functionally important.
Mechanistic interpretation is further complicated by the observation that PVT1 appears to be a ncRNA
since the longest open reading-frame predicted from our assessment of PVT1 sequences is 150 amino acids encoded in the first two exons. The ncRNAs most strongly implicated in cancer so far are miRNAs (29) . These 20-22 nucleotide RNAs are the result of enzymatic processing of larger transcripts and may operate in cancer by blocking translation of target genes to which they are complementary. Deregulated expression of several miRNAs has been associated with poor disease outcome in chronic lymphocytic leukemia, colorectal neoplasia, lung cancer and Burkitt lymphoma (29) . miRNAs are also frequently 19 located at fragile sites and genomic regions that are involved cancers (30) . Thus, we investigated the possibility of PVT1 as a miRNA. Our computational analyses show that the predicted sequences of PVT1 transcripts do not seem to have the 'stem-loop' structures normally associated with miRNAs (20, 31, 32) .
A recent study by Dr. Huppi has identified 7 putative miRNAs within the ~400kb PVT1 genomic locus (Private communication). The precursor sequence of one of these overlaps with exon 1b in our current study, but it also extends beyond the consensus splice site of the exon. The precursor sequences of the other 6 miRNAs have no association with any of the annotated PVT1 exons and might be results of extensive alternative splicing found in this locus ( Figure 2 and communications with Dr. Konrad Huppi).
This may explain our failure to identify potential miRNAs precursor sequences in our predicted PVT1 transcripts, which contain mostly known exons. Thus, the mechanism by which PVT1 exerts its pathological function remains unclear.
In conclusion, we have used our well-characterized cell line collection to demonstrate that amplification at 8q24 increases expression of both MYC and PVT1 and that both of these deregulated transcripts appear to contribute to ovarian and breast cancer pathophysiology. We have demonstrated that PVT1 is most likely an ncRNA that acts independently of MYC and when amplified and over expressed, acts to increase proliferation and inhibit apoptosis. Table S1 List of ovarian cancer cell lines used in the study Table S2 List of genes tested in Taqman® QPCR assays   Table S3 Gene copy numbers in 30 ovarian cell lines in genomic regions that were amplified or deleted in more than 20% ovarian tumors from study A and B of Kuo et al (21) . All the aCGH BAC clones listed in this table had gained or lost at least one copy (log 2 ratio>0.5 or <-0.5) in tumors from study A or B. Red boxes indicate gains of at least one copy and green boxes indicates losses of at least one copy. Dark red indicates high level amplification (log 2 ratio >3) and dark green indicates homozygous deletions (log 2 ratio < -2) 
